�@ Prof. Michihiko Kuwano
Department of Medical Biochemistry Graduate school of Medical Science

What is angiogenesis ?

Tumors cells need a rich blood supply in order to grow and metastasize. Angiogenesis is the process by which new blood vessels, called capillaries are formed. Capillaries are lined with endothelial cells.


¥Vascular endothelial growth factor receptor (VEGFR) inhibitor targets KDR tyrosine kinase. We demonstrated that A potent VEGFR tyrosine kinase inhibitor (VEGFR-TKI) also blocks Flt-1tyrosine kinase, which is another VEGF receptor. This compound inhibits migration of vascular endothelial cells in response to placenta growth factor (PlGF). Moreover, this compound inhibits PlGF-induced angiogenesis in Matrigel plug assay.
Anti-angiogenic activity of this compound appears to be because of inhibition of not only KDR but also Flt-1 tyrosine kinase.

¥Epidermal growth factor receptor (EGFR) tyrosine kinase is a potential target for anticancer therapy. We demonstrated that the antitumor effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) could be mediated in part by inhibition of tumor angiogenesis through direct effects on microvascular endothelial cells (EGFR-TKI inhibited EGF-induced formation of tube-like structures ) and also through reduced production of proangiogenic factors (VEGF, IL-8) by tumor cells.



>>Japanese page is here.